NewAmsterdam Pharma Company N.V. NAMS 深 沪
等待开盘 05-21 09:30:00 美东时间
35.91
+2.190
+6.49%
华盛通- 最 高36.035
- 今 开34.09
- 成交量 86.59万股
- 最 低 34.00
- 昨 收 33.72
- 总市值 41.98亿
- 52周最高 42.205
- 市盈率 静 --
- 换手率 0.74%
- 52周最低 17.63
- 委 比 -96.44%
- 总股本 1.17亿
- 历史最高 42.205
- 量 比 0.62
- 振 幅 6.03%
- 历史最低 5.6326
- 每 手 1
- 风险率 6.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Monster Beverage, Westrock Coffee, Himax Technologies And Other Big Stocks Moving Higher On Friday
US stocks, including Monster Beverage Corp, rose on Friday. Monster Beverage reported better-than-expected financial results, causing a 12.8% jump in their shares.
05-08 22:15
NewAmsterdam Pharma shares are trading higher after the company reported better-than-expected Q1 financial results.
NewAmsterdam Pharma shares are trading higher after the company reported better...
05-08 03:03
NewAmsterdam Pharma Q1 EPS $(0.40) Beats $(0.47) Estimate, Sales $3.040M Beat $936.364K Estimate
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.47) by 14.89 percent. This is a 17.65 percent decrease over losses of $(0.34) per share
05-07 20:41
NewAmsterdam Pharma Announces Chief Accounting Officer Transition Agreement
NewAmsterdam Pharma Company ( ($NAMS) ) has issued an announcement. On April 20...
04-25 05:48
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Company N.V. granted inducement share options covering 15,000 ordinary shares and restricted stock units covering 3,200 shares to two non-executive new hires under the 2024 Inducement Plan. The share options have an exercise price of $32.81, vesting over four years, with 25% after one year and the remainder in 36 monthly installments. Restricted stock units vest over three years, with one-third annually. Both grants were appro...
04-02 21:43
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
NewAmsterdam Pharma will present data on its novel, oral, low-dose CETP inhibitor, obicetrapib, at ACC.26. The presentations will focus on its potential to preserve kidney function, safety, and cardiovascular outcomes in patients with elevated LDL-C. Obicetrapib has shown significant LDL-lowering effects with a favorable safety profile in Phase 3 trials. The company is advancing its clinical development, including the Phase 3 PREVAIL trial, with ...
03-23 12:00
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma announced the approval of inducement share options covering 10,000 ordinary shares and restricted stock units (RSUs) for 2,200 shares, granted to two non-executive new hires. The share options have an exercise price of $32.83, vesting over four years, with 25% after one year and the remainder in 36 monthly installments. The RSUs vest over three years, with one-third vesting annually. Both grants align with the 2024 Inducement ...
03-06 21:01
美股大行评级 | 潜在涨幅108.69%！Stephens & Co.维持圣玛丽石油勘测"超配"评级，上调目标价至49美元
今日重点评级关注：Stephens & Co.：维持圣玛丽石油勘测"超配"评级，目标价从48美元升至49美元；花旗：维持IDEAYA Biosciences"买入"评级，目标价从64美元升至65美元
02-20 15:57
美股大行评级 | 潜在涨幅216.49%！杰富瑞上调BioAge Labs目标价至62美元，评级升至"买入"
今日重点评级关注：杰富瑞：上调BioAge Labs评级至"买入"，目标价从9美元升至62美元；RBC Capital：维持COMPASS Pathways Plc Sponsored ADR"跑赢大市"评级，目标价从21美元升至22美元
02-19 16:21
NewAmsterdam Pharma reports FY results
NewAmsterdam Pharma press release (NAMS): FY Revenue of $22.5M. Net loss for the year ended December 31, 2025, was $203.8 million, compared to net loss of $241.6 million in the year ended December 31,...
02-19 04:25
